Jump to contents

Researcher Information

last modified:2020/03/26

Professor YANO Seiji

Mail Laboratory Website

Faculty, Affiliation

Cancer Research Institute

College and School Educational Field

Division of Medical Sciences, Graduate School of Medical Science
Graduate School of Phamacy

Laboratory

Division of Medical Oncology TEL:076-265-2794 FAX:076-234-4524

Academic Background

【Academic background(Doctoral/Master's Degree)】
University of Tokushima Graduate School Doctor 199503 Completed
【Academic background(Bachelor's Degree)】
The University of Tokushima 199003
【Degree】
M.D., Ph.D.

Career

1997-2000 University of Tokushima Faculty of Medicine Dept of Int Med Mol Ther Assistant Professor(1997/01/01-2000/09/30)
2000-2007 Tokushima University Hospital Lecturer(2000/10-)
Kanazawa University Cancer Research Institute(2007/04/01-)

Year & Month of Birth

1965/09

Academic Society

Japanese Cancer Association
Japanese Society of Medical Oncology
Japanese Respiratory Society
Japanese Association for Metastasis Research
Japanese Society of Internal Medicine
Japan Lung Cancer Society
Japan Society of Clinical Oncology
Japane Society for Respiratory Endoscopy
American Association for Cancer Research
American Society of Clinical Oncology

Award

○JAMR Young Investigator Award(1998/10)
○Investigators Award University of Tokushima School of Medicine(1998/09)
○Grant Kanae Foundation for the Promotion of Medical Science(2000/10)
○Incitement Award of the Japanese Cancer Association(2005/09)
○Grant Sankyo Foundation for Life Science(2006/01)
○The Mitani Foundation for Research and Development(2008/07)
○Kobayashi Foundation for Cancer Research(2009/06)
○Kobayashi Foundation for Cancer Research(2009/06)
○JCA Mauvernay Award (Applied)(2013/10/05)
○JCA Mauvernay Award (Applied)(2013/10/05)
○JCA Mauvernay Award (Applied)(2013/10/05)
○JCA Mauvernay Award (Applied)(2013/10/05)

Specialities

Respiratory organ internal medicine

Speciality Keywords

Cancer drug therapy, Lung cancer metastasis, molecular targeted therapy, drug resistance

Research Themes

Molecular targeted therapy for malignant pleural mesothelioma

Elucidation of multiple-organ metastasis by lung cancer

Study of molecular mechanisms which induces resistance against molecular targeted drugs

Books

Papers

  •  Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report. Adachi Y, Yanagimura N, Suzuki C, Ootani S, Tanimoto A, Nishiyama A, Yamashita K, Ohtsubo K, Takeuchi S, Yano S. BMC Cancer 2020
  •  ONO-7475, a novel AXL inhibitor, suppresses the adaptive resistance to initial EGFR-TKI treatment in EGFR-mutated non-small lung cancer. Okura N, Nishioka N, Yamada T, Taniguchi H, Tanimura K, Katayama Y, Yoshimura A, Watanabe S, Kikuchi T, Shiotsu S, Kitazaki T, Nishiyama A, Iwasaku M, Kaneko Y, Uchino J, Uehara H, Horinaka M, Sakai T, Tanaka K, Kozaki R, Yano S, Takayama K. Clin Cancer Res 2020
  •  Osimertinib overcomes alectinib resistance caused by amphiregulin in a leptomeningeal carcinomatosis model of ALK-rearranged lung cancer. Arai S, Takeuchi S, Fukuda K, Taniguchi H, Nishiyama A, Tanimoto A, Satouchi M, Yamashita K, Ohtsubo K, Nanjo S, Kumagai T, Katayama R, Nishio M, Zheng MM, Wu YL, Nishihara H, Yamamoto T, Nakada M, Yano S. J Thorac Oncol 2020
  •  Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/EGFR mutation double-positive lung cancer. Takeuchi S, Hase T, Shimizu S, Ando M, Hata A, Murakami H, Kawakami T, Nagase K, Yoshimura K, Fujiwara T, Tanimoto A, Nishiyama A, Arai S, Fukuda K, Katakami N, Takahashi T, Hasegawa Y, Ko TK, Ong ST, Yano S. Cancer Sci 111 561-570 2020
  •  EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression. Peng S, Wang R, Zhang X, Ma Y, Zhong L, Li K, Nishiyama A, Arai S, Yano S, Wang W. Mol Cancer 18 165 2019

show all

  •  Analyses of aberrant methylation of tumor suppressive miRNAs in bile in patients with pancreaticobiliary diseases. Ohtsubo K, Miyake K, Arai S, Fukuda K, Yanagimura N, Suzuki C, Otani S, Adachi Y, Tanimoto A, Nishiyama A, Yamashita K, Takeuchi S, Notohara K, Yoshimura K, Yano S. Anticancer Res. 39 5449-5459 2019
  •  Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance. Kita K, Fukuda K, Takahashi H, Tanimoto A, Nishiyama A, Arai S, Takeuchi S, Yamashita K, Ohtsubo K, Otani S, Yanagimura N, Suzuki C, Ikeda H, Tamura M, Matsumoto I, Yano S.  Cancer Sci 110 3215-3224 2019
  •  Clinical characteristics associated with lenvatinib-induced fistula and tumor-related bleeding in patients with thyroid cancer. Staub Y, Nishiyama A, Suga Y, Fujita M, Matsushita R, Yano S. Anticancer Res 39 3871-3878 2019
  •  Phase I/II study of intermitted erlotinib in combination with docetaxel in patients with recurrent non-small cell lung cancer (WJOG4708L).  Kimura T, Kawaguchi T, Chiba Y, Yoshioka H, Watanabe K, Kijima T, Kogure Y, Oguri T, Yoshimura N, Niwa T, Kasai T, Hayashi H, Ono A, Asai K, Tanaka H, Yano S, Yamamoto N, Nakanishi Y, Nakagawa K. Jpn J Clin Oncol. 2019
  •  Distinct localization of mature HGF from its precursor form in developing and repairing stomach. Jangphattananont N, Sato H, Imamura R, Sakai K, Terakado Y, Murakami K, Barker N, Oshima H, Oshima M, Takagi J, Kato Y, Yano S, Matsumoto K. Int J Mol Sci. 20 2019
  •  Caput medusae-like venous dilatations in lung cancer. Adachi Y, Yano S. Internal Med. 2019
  •  Macrocyclic peptide-based inhibition and imaging of hepatocyte growth factor. Sakai K, Passioura T, Sato H, Ito K, Furuhashi H, Umitsu M, Takagi J, Kato Y, Mukai H, Warashina S, Zouda M, Watanabe Y, Yano S, Shibata M, Suga H, Matsumoto K. Nat Chem Biol 15 598-606 2019
  •  Distribution and efficacy of lenvatinib in brain metastasis of human anaplastic thyroid cancer cells in severe combined immune-deficient mice. Wang R, Yamada T, Arai S, Fukuda K, Taniguchi H, Tanimoto A, Nishiyama A, Takeuchi S, Yamashita K, Ohtsubo K, Matsui J, Onoda N, Hirata E, Taira S, Yano S. Mol Cancer Ther 18 947-956 2019
  •  Epithelial-to-mesenchymal transition is a mechanism of ALK inhibitor resistance in lung cancer independent of ALK mutation status.  Fukuda K, Takeuchi S, Arai S, Katayama R, Nanjo S, Tanimoto A, Nishiyama A, Nakagawa T, Taniguchi H, Suzuki T, Yamada T, Nishihara H, Ninomiya H, Ishikawa Y, Baba S, Takeuchi K, Horiike A, Tanagitani N, Nishio K, Yano S.  Cancer Res 79 1658-1670 2019
  •  AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells. Taniguchi H, Yamada T, Wang R, Tanimura K, Adachi Y, Nishiyama A, Tanimoto A, Takeuchi S, Araujo LH, Boroni M, Yoshimura A, Shiotsu S, Matsumoto I, Watanabe S, Kikuchi T, Miura S, Tanaka H, Kitazaki T, Yamaguchi H, Mukae H, Uchino J, Uehara H, Takayama K, Yano S.  Nat Commun 10 259 2019
  •  Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case report.  Tanimoto A, Takeuchi S, Kotani H, Yamashita K, Tamada T, Ohtsubo K, Ebi H, Ikeda H, Yano S. BMC Pulmonary Medicine 18 193 2018
  •  A case of advanced pancreatic neuroendocrine tumor in which octreotide long-acting repeatable was effective after failure of everolimus and sunitinib. Kitade H, Ohtsubo K, Hokkoku K, Mori M, Osamura RY, Sakuma H, Nakai M, Yano S. Int. Cancer Conference J. 8 24-28 2018
  •  Cancer stem-like properties and gefitinib resistance are dependent on purine synthetic metabolism mediated by the mitochondrial enzyme MTHFD2. Nishimura T, Nakata A, Xiaoxi C, Nishi K, Meguro-Horike M, Sasaki S, Kita K, Horike S, Saitoh K, Kato K, Igarashi K, Murayama T, Kohno S, Takahashi C, Mukaida N, Yano S, Soga T, Tojo A, Gotoh N. Oncogene 2018
  •  Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC. Arasada RR, Shilo K, Yamada T, Zhang J, Yano S, Ghanem R, Wang W, Takeuchi S, Fukuda K, Katakami N, Tomii K, Ogushi F, Nishioka Y, Talabere T, Misra S, Duan W, Fadda P, Rahman MA, Nana-Sinkam P, Evans J, Amann J, Tchekneva EE, Dikov MM, Carbone DP. Nat Commun 9 3198 2018
  •  Foretinib overcomes entrectinib resistance associated with the NTRK1 G667C mutation in NTRK1 fusion-positive tumor cells in a brain metastasis model. Nishiyama A, Yamada T, Kita K, Wang R, Arai S, Fukuda K, Tanimoto A, Takeuchi S, Tange S, Tajima A, Furuya N, Kinoshita T, Yano S. Clin Cancer Res 24 2357-2369 2018
  •  Histone deacetylase inhibition enhances the antitumor activity of a MEK inhibitor in lung cancer cells harboring RAS mutations. Yamada T, Amann JM, Tanimoto A, Taniguchi H, Shukuya T, Timmers C, Yano S, Shilo K, Carbone DP. Mol Cancer Ther 17 17-25 2018
  •  In vivo imaging xenograft models for the evaluation of anti-brain-tumor efficacy of targeted drugs. Kita K, Arai S, Nishiyama A, Taniguchi H, Fukuda K, Wang R, Yamada T, Takeuchi S, Tange S, Tajima A, Nakada M, Yasumoto K, Motoo Y, Murakami T, Yano S.  Cancer Med 6 2972-2983 2018
  •  Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers. Kotani H, Adachi Y, Kitai H, Tomida S, Bando H, Faber AC, Yoshino T, Voon DC, Yano S, Ebi H.  Oncogene 37 1775-1787 2018
  •  Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer.  Adachi Y, Watanabe K, Kita K, Kitai H, Kotani H, Sato Y, Inase N, Yano S, Ebi H Carcinogenesis  38 1063-1072 2017
  •  Androgen replacement therapy for cancer-related symptoms in male advanced cancer patients: study protocol for a randomised prospective trial (ARTFORM study). Izumi K, Shigehara K, Nohara T, Narimoto K, Kadono Y, Nanjo S, Yamada T, Ohtsubo K, Yano S, Mizokami A. J Med Invest 64 202-204 2017
  •  Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway. Taniguchi H, Yamada T, Takeuchi S, Arai S, Fukuda K, Sakamoto S, Kawada M, Yamaguchi H, Mukae H, Yano S. Cancer Sci 108 1378-1385 2017
  •  Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation. Takeuchi S, Fukuda K, Yamada T, Arai S, Takagi S, Ishii G, Ochiai A, Iwakiri S, Itoi K, Uehara H, Nishihara H, Fujita N, Yano S. Cancer Sci 108 1378-1385 2017
  •  A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer. Soh SX, Siddiqui FJ, Allen JC, Kim GW, Lee JC, Yatabe Y, Soda M, Mano H, Soo RA, Chin TM, Ebi H, Yano S, Matsuo K, Niu X, Lu S, Isobe K, Lee JH, Yang JC, Zhao M, Zhou C, Lee JK, Lee SH, Lee JY, Ahn MJ, Tan TJ, Tan DS, Tan EH, Ong ST, Lim WT. Oncotarget 8 41474-86 2017
  •  The case of double primary lung adenocarcinomas with an EGFR mutation and ALK translocation successfully treated with alectinib at the post-surgical recurrence. Tsunezuka Y, Tanaka N, Fujimori H, Togashi Y, Baba S, Takeuchi K, Katayanagi K, Kurumaya H, Kitade H, Atagi S, Yano S. J Med Invest 64 305-307 2017
  •  In vitro and in vivo anti-tumor activity of alectinib in tumor cells with NCOA4-RET. Arai S, Kita K, Tanimoto A, Takeuchi T, Fukuda K, Sato H, Yano S. Oncotarget 8 73766-7 2017
  •  Phase I/II study of alectinib in lung cancer with RET fusion gene: study protocol. Takeuchi S, Murayama T, Yoshimura K, Kawakami T, Takahara S, Imai Y, Kuribayashi Y, Nagase K, Goto K, Nishio M, Hasegawa Y, Satouchi M, Kiura K, Seto T, Yano S. J Med Invest 65 317-320 2017
  •  Phase I study of combined therapy with vorinostat and gefitinib to treat BIM deletion polymorphism-associated resistance in EGFR-mutant lung cancer (VICTROY-J): a study protocol. Takeuchi S, Yoshimura K, Fujiwara T, Ando M, Shimizu S, Nagase K, Hasegawa Y, Takahashi T, Katakami N, Inoue A, Yano S. J Med Invest 64 321-325 2017
  •  MET copy number gain is associated with gefitinib resistance in leptomeningeal carcinomatosis of EGFR-mutant lung cancer. Nanjo S, Arai S, Wang W, Takeuchi S, Yamada T, Hata A, Katakami N, Okada Y, Yano S. Mol Cancer Ther 16 506-515 2017
  •  Amphiregulin triggered EGFR activation confers crizotinib-resistance in a mouse model with EML4-ALK cancer and its circumvention with EGFR inhibitors. Taniguchi H, Takeuchi S, Fukuda K, Nakagawa T, Arai S, Yamada T, Yamaguchi H, Mukae H, Yano S. Cancer Sci 108 53-60 2017
  •  Antitumor vascular strategy for controlling experimental metastatic spread of human small cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficiency mice. Yano S, Muguruma H, Matsumori Y, Goto H, Nakataki E, Edakuni N, Tomimoto H, Kakiuchi S, Yamamoto A, Uehara H, Ryan A, Sone S. CLINICAL CANCER RESEARCH 11 24 8789-8798 2005/12
  •  Reveromycin A inhibits osteolytic bone metastasis of small-cell lung cancer cells, SBC-5, through an anti-osteoclastic activity. Muguruma H, Yano S, Kakiuchi S, Uehara H, Kawatani K, Osada H, Sone S. CLINICAL CANCER RESEARCH 11 24 8822-8828 2005/12
  •  A novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor. Nakataki E, Yano S, Matsumori Y, Goto H, Kakiuchi S, Muguruma H, Bando Y, Uehara H, Hamada H, Kito K, Yokoyama A, Sone S. CANCER SCIENCE 97 3 183-191 2006/05
  •  Restored expression of MYO18B gene suppresses orthotopic growth and production of bloody pleural effusion by human malignant pleural mesothelioma cells in SCID mice. Edakuni N, Ikuta K, Yano S, Nakataki E, Muguruma H, Uehara H, Tani M, Yokota J, Aizawa H, Sone S. ONCOLOGY RESEARCH 16 5 235-243 2006/10
  •  Levels of soluble vascular endothelial growth factor receptor 1 are elevated in the exudative pleural effusions. Tomimoto H, Yano S, Muguruma H, Kakiuchi S, Sone S. JOURNAL OF MEDICAL INVESTIGATION 54 1 146-153 2007/02
  •  Autofluorescence bronchoscopy, a novel modality for the early detection of bronchial premalignant and malignant lesions. Hanibuchi M, Yano S, Nishioka Y, Miyoshi T, Kondo K, Uehara H, Sone S. JOURNAL OF MEDICAL INVESTIGATION 54 261-266 2007
  •  The therapeutic efficacy of anti-vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in SCID mice. Li Q, Yano S, Ogino H, Wang W, Uehara H, Nishioka Y, Sone S.  CLINICAL CANCER RESEARCH 13 5918-5925 2007
  •  Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma cells with EGF receptor mutations.  Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, Ogino H, Kakiuchi S, Hanibuchi M, Nishioka Y, Uehara H, Mitsudomi T, Yatabe Y, Nakamura T, Sone S. Cancer Research 68 9479-9487 2008
  •  Lysophosphoatidic acid stimulated proliferation and motility of malignant pleural mesothelioma cells through LPA receptors, LPA1 and LPA2. Yamada T, Yano S, Ogino H, Ikuta K, Kakiuchi S, Hanibuchi M, Taniguchi, Sekido Y, Sone S.  Cancer Science 99 1603-1610 2008
  •  Follistatin suppresses the production of experimental multiple-organ metastasis by small cell lung cancer cells in NK cell-depleted SCID mice.  Ogino H, Yano S, Kakiuchi S, Muguruma H, Ikuta K, Uehara H, Tsuchida K, Sugino H, Sone S.  CLINICAL CANCER RESEARCH 14 660-667 2008
  •  E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles. Ikuta K, Yano S, Trung VT, Hanibuchi M, Goto H, Li Q, Wang W, Yamada T, Ogino H, Kakiuchi S, Uehara H, Sekido Y, Uenaka T, Nishioka Y, Sone S. CLINICAL CANCER RESEARCH 15 7229-7237 2009
  •  Cancer of unknown primary site in which tumor marker-oriented chemotherapy was effective and pancreatic cancer was finally confirmed at autopsy.  Ohtsubo K, Watanabe H, Yamada T, Tsuchiyama T, Mouri H, Yamashita K, Yasumoto K, Ikeda H, Nakanuma Y, Yano S. Internal Medicine 48 1651-1656 2009
  •  Combined chemotherapy with carboplatin plus irinotecan showed favorable efficacy in a case with relapsed small cell carcinoma of the prostate complicated with meningeal carcinomatosis. Yamada T, Ohtsubo K, Mouri H, Yamashita K, Yasumoto K, Izumi K, Zen Y, Watanabe H, Yano S.  International Journal of Clinical Oncology 14 468-472 2009
  •  Crosstalk to stromal fibroblasts induces resistance of lung cancer to EGFR tyrosine kinase inhibitors. Wang W, Li Q, Yamada T, Matsumoto K, Matsumoto I, Oda M, Watanabe G, Kayano Y, Nishioka Y, Sone S, Yano S.  CLINICAL CANCER RESEARCH 15 6630-6638 2009
  •  A bone metastasis model with osteolytic and osteoblastic properties of human lung cancer ACC-LC-319/bone2 in natural killer cell-depleted severe combined immunodeficient mice. Otsuka S, Hanibuchi M, Ikuta K, Yano S, Goto H, Ogino H, Yamada T, Kakiuchi S, Nishioka Y, Takahashi T, Sone S.  Oncology Research 17 581-591 2009
  •  Intensification therapy of anti-parathyroid hormone-related protein antibody combined with zoledronic acid for bone metastasis of small cell lung cancer cells in severe combined immunodeficient mice. Yamada T, Muguruma H, Yano S, Ikuta K, Ogino H, Kakiuchi S, Hanibuchi M, Uehara H, Nishioka Y, Sone S. Molecular Cancer Therapeutics 8 119-126 2009
  •  The role of percutaneous needle biopsy in differentiation of renal tumors.  Izumi K, Narimoto K, Sugimoto K, Kobori Y, Maeda Y, Mizokami A, Koh E, Yamada T, Yano S, Namiki M.  Japanese Journal of Clinical Oncology 40 1081-1086 2010
  •  Epidemiological and clinical features of lung cancer patients from 1999 to 2009 in Tokushima Prefecture of Japan.  Kanematsu T, Hanibuchi M, Tomimoto H, Sakiyakma S, Kenzaki K, Kondo K, Bando H, Haku T, Yoneda K, Hirose T, Toyoda Y, Goto H, Sakaguchi S, Kinoshita K, Azuma M, Kakiuchi S, Kishi J, Azuma M, Tada H, Sumitomo M, Nishioka Y, Yano S, Sone S.  The Journal of Medical Investigation 57 326-333 2010
  •  Metastatic renal cell carcinoma complicated with diffuse alveolar hemorrhage: a rare adverse effect of sunitinib. Yamada T, Ohtsubo K, Izumi K, Takeuchi S, Mouri H, Yamashita K, Yasumoto K, Ghenev P, Kitagawa S, Yano S. International Journal of Clinical Oncology 15 638-641 2010
  •  Gender difference in bone metastasis of human small cell lung cancer, SBC-5 cells in natural killer-cell depleted severe combined immunodeficient mice. Sakaguchi S, Goto H, Hanibuchi M, Otsuka S, Ogino H, Kakiuchi S, Uehara H, Yano S, Nishioka Y, Sone S. Clinical and Experimental Metastasis 27 351-359 2010
  •  Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer. Yamada T, Matsumoto K, Wang W, Li Q, Nishioka Y, Sone S, Yano S. CLINICAL CANCER RESEARCH 16 174-183 2010
  •  Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2 expressing small cell lung cancer.  Yamada T, Bando H, Takeuchi S, Kita K, Li Q, Wang W, Akinaga S, Nishioka Y, Sone S, Yano S.  CANCER SCIENCE 102 2157-2163 2011
  •  Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.  Yano S, Yamada T, Takeuchi S, Tachibana K, Minami Y, Yatabe Y, Mitsudomi T, Tanaka H, Kimura T, Kudoh S, Nokihara H, Ohe Y, Yokota J, Uramoto U, Yasumoto Y, Kiura K, Higashiyama M, Oda M, Saito H, Yoshida J, Kondoh K, Noguchi M. Journal of Thoracic Oncology 6 2011-2017 2011
  •  Pleural mesothelioma instigates tumor associated fibroblasts to promote progression via malignant cytokine network.  Li Q, Wang W, Yamada T, Matsumoto K, Bando Y, Uehara H, Nishioka Y, Sone S, Iwakiri S, Itoi K, Utsugi T, Yano S. American Journal of Pathology 179 1483-1493 2011
  •  E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor.  Ogino H, Hanibuchi M, Kakiuchi S, Trung Van The, Goto H, Ikuta K, Yamada T, Uehara H, Tsuruoka A, Uenaka T, Wang W, Li Q, Takeuchi S, Yano S, Nishioka Y, Sone S. Molecular Cancer Therapeutics 10 1218-1228 2011
  •  A multi-institutional phase II study of combination chemotherapy with S-1 plus cisplatin in patients with advanced non-small cell lung cancer. Tomimoto H, Hanibuchi M, Ogushi F, Okano Y, Shinohara T, Doi H, Yamamoto A, Takeuchi E, Yamamoto A, Azuma M, Tada H, Kanematsu T, Kakiuchi S, Goto H, Yano S, Nishioka Y, Sone S. Oncology Letter 2 465-470 2011
  •  Enhancement of osteoclastogenic activity in osteolytic prostate cancer cells by physical contact with osteoblasts. Shiirevnyamba A, Takahashi T, Shan H, Ogawa H, Yano S, Kanayama H, Izumi K, Uehara H.  British Journal of Cancer 104 505-513 2011
  •  Reaction of plasma hepatocyte growth factor level in lung cancer patients treated with EGFR-TKIs. Tanaka H, Kimura T, Kudoh S, Mitsuoka S, Watanabe T, Suzumura T, Tachibana K, Noguchi M, Yano S, Hirata K. International Journal of Cancer 126 1410-1416 2011
  •  Epithelioid glioblastoma changed to typical glioblastoma -the methylation status of MGMT promoter and 5-ALA fluorescence -. Tanaka S, Nakada M, Hayashi Y, Nakada S, Kitamura-Sawada S, Furuyama N, Suzuki T, Kamide T, Hayashi Y, Yano S, Hamada JI. Brain Tumor Pathology 28 59-64 2011
  •  Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma. Kurai J, Chikumi H, Hashimoto K, Takata M, Sako T, Yamaguchi K, Kinoshita N, Watanabe M, Touge H, Makino H, Igishi T, Hamada H, Yano S, Shimizu E. International Journal of Oncology 41 1610-1618 2012
  •  Endoscopic findings of upper gastrointestinal lesions in patients with pancreatic cancer. Ohtsubo K, Watanabe H, Mouri H, Yamashita K, Yasumoto K, Yano S. JOURNAL OF ONCOLOGY PRACTICE 13 420-426 2012
  •  Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor to overcome erlotinib resistance in EGFR mutant lung cancer. Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S. Molecular Cancer Therapeutics 11 2149-2157 2012
  •  Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer. Takeuchi S, Wang W, Li Q, Yamada T, Kita K, Donev IS, Nakamura T, Matsumoto K, Mukaida N, Shimizu E, Nishioka Y, Sone S, Uenaka T, Yano S.  American Journal of Pathology 181 1034-1043 2012
  •  Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor-resistance in EML4-ALK lung cancer cells. Yamada T, Takeuchi S, Nakade J, Kita K, Nakagawa T, Nanjo S, Nakamura T, Matsumoto K, Soda M, Mano H, Yano S. CLINICAL CANCER RESEARCH 18 3592-3602 2012
  •  Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR mutant lung cancer by decreasing client protein expression and angiogenesis. Koizumi H, Yamada T, Takeuchi S, Nakagawa T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Yano S. Journal of Thoracic Oncology 7 1078-1085 2012
  •  E7050, a Met kinase inhibitor, reverses three different mechanisms of hepatocyte growth factor-induced resistance to tyrosine kinase inhibitors in EGFR mutant lung cancer cells. Wang W, Li Q, Takeuchi S, Yamada T, Koizumi H, Nakamura T, Matsumoto K, Mukaida N, Nishioka Y, Sone S, Uenaka T, Yano S. CLINICAL CANCER RESEARCH 18 1663-1671 2012
  •  Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer.  Yamada T, Takeuchi S, Kita K, Bando H, Nakamura T, Matsumoto K, Yano S. Journal of Thoracic Oncology 7 272-280 2012
  •  A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody. Abe S, Morita Y, Kaneko MK, Hanibuchi M, Tsujimoto Y, Goto H, Kakiuchi S, Aono Y, Huang J, Sato S, Kishuku M, Taniguchi Y, Azuma M, Kawazoe K, Sekido Y, Yano S, Akiyama S, Sone S, Minakuchi K, Kato Y, Nishioka Y. The Journal of Immunology 190 6239-6249 2013
  •  Synchronous triple cancers of the pancreas, stomach, and cecum treated with S-1 followed by pancrelipase treatment of pancreatic exocrine insufficiency. Ohtsubo K, Ishikawa D, Nanjo S, Takeuchi S, Yamada T, Mouri H, Yamashita K, Yasumoto K, Gabata T, Matsui O, Ikeda H, Takamatsu Y, Iwakami S, Yano S. JOURNAL OF ONCOLOGY PRACTICE 14 515-520 2013
  •  PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1.  Ebi H, Costa C, Fabera AC, Nishtalaa M, Kotanib H, Jurica D, Pellea PD, Songa Y, Yano S, Mino-Kenudsona M, Benesa CH, Engelman JA. Proceedings of the National Academy of Sciences USA 110 21124-21129 2013
  •  Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors. Nanjo S, Yamada T, Nishihara H, Takeuchi S, Sano T, Nakagawa T, Ishikawa D, Zhao L, Ebi H, Yasumoto K, Matsumoto K, Yano S. PLOS ONE 8 12 84700 2013
  •  Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer. Zhao L, Yasumoto K, Kawashima A, Nakagawa T, Takeuchi S, Yamada T, Matsumoto K, Yonekura K, Yoshie O, Yano S. CANCER SCIENCE 104 1640-1646 2013
  •  KDM5B histone demethylase controls epithelial-mesenchymal transition of cancer cells by regulating the expression of the microRNA-200 family. Enkhbaatar Z, Terashima M, Oktyabri D, Tange S, Ishimura A, Yano S, Suzuki T. Cell Cycle 12 2100-2112 2013
  •  mTOR inhibitors control erlotinib-resistance of EGFR mutant lung cancer cells triggered by HGF. Ishikawa D, Takeuchi S, Nakagawa T, Sano T, Nakade J, Nanjo S, Yamada T, Ebi H, Nakamura T, Matsumoto K, Kagamu H, Yoshizawa H, Yano S. PLOS ONE 8 5 62104 2013
  •  EGFR-TKI resistance due to BIM polymorphism can be circumvented by in combination with HDAC inhibition. Nakagawa T, Takeuchi S, Yamada T, Ebi H, Sano T, Nanjo S, Ishikawa D, Sato M, Hasegawa Y, Sekido Y, Yano S. Cancer Research 73 2428-2434 2013
  •  Surfactant protein a suppresses lung cancer progression by regulating the polarization of tumor-associated macrophages. Mitsuhashi A, Goto H, Kuramoto T, Tabata S, Yukishige S, Abe S, Hanibuchi M, Kakiuchi S, Saijo A, Aono Y, Uehara H, Yano S, Ledford JG, Sone S, Nishioka Y. American Journal of Pathology 182 1843-1853 2013
  •  Novel PI3K-mTOR inhibitor, BEZ235, circumvents erlotinib-resistance of EGFR mutant lung cancer cells triggering by HGF. Sano T, Takeuchi S, Nakagawa T, Ishikawa D, Nanjo S, Yamada T, Nakamura T, Matsumoto K, Yano S.  International Journal of Cancer 113 505-513 2013
  •  Scaffold Aki1, a novel therapeutic target for lung cancer with epidermal growth factor receptor mutations. Yamada T, Takeuchi S, Fujita N, Nakamura A, Wang W, Li Q, Oda M, Mitsudomi T, Yatabe Y, Sekido Y, Yoshida J, Higashiyama M, Noguchi M, Uehara H, Nishioka Y, Sone S, Yano S.  Oncogene 32 4427-4435 2013
  •  Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells. Tanimoto A, Yamada T, Takeuchi S, Ebi H, Kita K, Matsumoto K, Yano S. Oncotarget 5 4920-4928 2014
  •  Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma. Moriya M, Yamada T, Tamura M, Ishikawa D, Alireza HM, Matsumoto I, Klepetko W, Oda M, Yano S, Watanabe G. Oncology Reports 32 1109-1115 2014
  •  TAS-115, a novel inhibitor of VEGFR-2 and Met, combined with erlotinib prevented re-growth of HGF-triggered erlotinib resistant lung cancer harboring EGFR mutation. Nakade J, Takeuchi S, Nakagawa T, Ishikawa D, Sano T, Nanjo N, Yamada T, Ebi H, Zhao Lu, Yasumoto K, Matsumoto M, Yonekura K, Yano S. Journal of Thoracic Oncology 9 775-783 2014
  •  Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab. Mitsuhashi A, Goto H, Saijo A, Trung VT, Aono Y, Ogino H, Kuramoto T, Tabata S, Uehara H, Izumi K, Yoshida M, Kobayashi H, Takahashi H, Gotoh M, Kakiuchi S, Hanibuchi M, Yano S, Yokomise H, Sakiyama S, Nishioka Y. Nature Communications 6 8792 2015
  •  Akt kinase-interacting protein1 signals through CREB to drive diffuse malignant mesothelioma. Yamada T, Amann JM, Fukuda K, Takeuchi S, Fujita N, Uehara H, Iwakiri S, Itoi K, Shilo K, Yano S, Carbone DP. Cancer Research 75 4188-4197 2015
  •  Elevated β-catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugs. Nakata A, Yoshida R, Yamaguchi R, Yamauchi M, Tamada Y, Fujita A, Shimamura T, Imoto S, Higuchi T, Nomura M, Kimura T, Nokihara H, Higashiyama M, Kondoh K, Nishihara H, Tojo A, Yano S, Miyano S, Gotoh N. Scientific Reports 5 13076 2015
  •  Crucial roles of RSK in cell motility by catalyzing serine phosphorylation of EphA2. Zhou Y, Yamada N, Tanaka T, Hori T, Yokoyama S, Hayakawa Y, Yano S, Fukuoka J, Koizumi K, Saiki I, Sakurai H. Nature Communications 6 7679 2015
  •  LPP inhibits collective cell migration during lung cancer dissemination. Kuriyama S, Yoshida M, Yano S, Aiba N, Kohno T, Minamiya Y, Goto A, Tanaka M. Oncogene 35 952-964 2015
  •  In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line.  Nanjo S, Nakagawa T, Takeuchi S, Kita K, Fukuda K, Nakada M, Uehara H, Nishihara H, Hara E, Uramoto H, Tanaka F, Yano S.  CANCER SCIENCE 106 244-252 2015
  •  Lack of association between the BIM deletion polymorphism and the risk of lung cancer with and without EGFR mutations. Ebi H, Oze I, Nakagawa T, Ito H, Hosono S, Matsuda F, Takahashi M, Takeuchi S, Sakao Y, Hida T, Faber, AC, Tanaka H, Yatabe Y, Mitsudomi T, Yano S,, Matsuo K. Journal of Thoracic Oncology 10 59-66 2015
  •  Amphiregulin triggered EGFR activation confers crizotinib-resistance in a mouse model with EML4-ALK cancer and its circumvention with EGFR inhibitors. Taniguchi H, Takeuchi S, Fukuda K, Nakagawa T, Arai S, Yamada T, Yamaguchi H, Mukae H, Yano S. CANCER SCIENCE 2016
  •  Recurrence of renal cell carcinoma diagnosed using contralateral adrenal biopsy with endoscopic ultrasound-guided fine-needle aspiration. Tanimoto A, Takeuchi S, Yaegashi H, Kotani H, Kitai H, Nanjo S, Ebi H, Yamashita K, Mouri H, Ohtsubo K, Ikeda H, Yano S. Molecular and Clinical Oncology 4 4 537-540 2016
  •  Elevated prothrombin time/international normalized ratio associated with concurrent administration of regorafenib and warfarin in a patient with advanced colorectal cancer. Kitade H, Hiromasa-Yamasaki A, Hokkoku K, Mori M, Watanabe M, Nakai M, Yano S. Journal of Pharmaceutical Health Care and Sciences 2 15 2016
  •  Proteolytic inactivation of anti-angiogenic vasohibin-1 by cancer cells. Saito M, Suzuki Y, Yano S, Miyazaki T, Sato Y. J Biochem 160 227-232 2016
  •  Epithelial-to-mesenchymal transition defines feedback activation of receptor tyrosine kinase signaling induced by MEK inhibition in KRAS mutant lung cancer.  Kitai H, Ebi H, Tomida S, Floros KV, Kotani H, Adachi Y, Oizumi S, Nishimura M, Faber AC, Yano S. Cancer Discovery 7 754-769 2016
  •  TMPRSS4 Expression as a Marker of Recurrence in Patients with Lung Cancer. Chikaishi Y, Uramoto H, Koyanagi Y, Yamada S, Yano S, Tanaka F.  Anticancer Research 36 121-127 2016
  •  Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression. Kotani H, Ebi H, Kitai H, Nanjo S, Kita K, Huynh TG, Ooi A, Faber AC, Mino-Kenudson M, Yano S. Oncogene 35 3587-3597 2016
  •  High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells. Nanjo S, Ebi H, Arai S, Takeuchi T, Yamada T, Mochizuki S, Okada Y, Nakada M, Murakami T, Yano S. Oncotarget 7 3847-3856 2016
  •  Hsp90 inhibition combined with zoledronic acid controls multiple organ metastases of chemotherapy-refractory small cell lung cancer cells. Takeuchi S, Fukuda K, Arai S, Nanjo S, Kita K, Yamada T, Hara E, Nishihara H, Uehara H, Yano S.  International Journal of Cancer 138 1281-1289 2016
  •  Antiangiogenic therapies for malignant pleural mesothelioma Yano, Seiji;Li, Qi;Wang, Wei;Yamada, Tadaaki;Takeuchi, Shinji;Nakataki, Emiko;Ogino, Hirokazu;Goto, Hisatsugu;Nishioka, Yasuhiko;Sone, Saburo FRONTIERS IN BIOSCIENCE-LANDMARK 16 0 740-748 2011
  •  Prognostic Value of Aquired Resistance-related Molecules in Japanese Patients with NSCLC Treated with an EGFR-TKI Uramoto, Hidetaka;Yamada, Tadaaki;Yano, Seiji;Kondo, Nobuyuki;Hasegawa, Seiki;Tanaka, Fumihiro ANTICANCER RESEARCH 32 9 3785-3790 2012
  •  HGF-MET in Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Yano, Seiji;Wang, Wei;Li, Qi;Yamada, Tadaaki;Takeuchi, Shinji;Matsumoto, Kunio;Nishioka, Yasuhiko;Sone, Saburo CURRENT SIGNAL TRANSDUCTION THERAPY 6 2 228-233 2011
  •  Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer Donev, Ivan S.;Wang, Wei;Yamada, Tadaaki;Li, Qi;Takeuchi, Shinji;Matsumoto, Kunio;Yamori, Takao;Nishioka, Yasuhiko;Sone, Saburo;Yano, Seiji CLINICAL CANCER RESEARCH 17 8 2260-2269 2011
  •  Molecular targeted therapy in metastatic melanoma and thyroid cancer Yamashita, Kaname; Yano, Seiji Japanese Journal of Chest Diseases 73 2 180-190 2014/02/01 
  •  Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement. Ogino H, Yano S, Kakiuchi S, Yamada T, Ikuta K, Nakataki E, Goto H, Hanibuchi M, Nishioka Y, Ryan A, Sone S. 265(1) 55-66 2008/01
  •  The therapeutic efficacy of a autofluorescence bronchoscopy, a novel modality for the early detection of bronchial premalignant and malignant lesions. 54 3 261-266 2007/08
  •  Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma Li, Qi;Wang, Wei;Machino, Yusuke;Yamada, Tadaaki;Kita, Kenji;Oshima, Masanobu;Sekido, Yoshitaka;Tsuchiya, Mami;Suzuki, Yui;Nan-ya, Ken-ichiro;Iida, Shigeru;Nakamura, Kazuyasu;Iwakiri, Shotaro;Itoi, Kazumi;Yano, Seiji CANCER SCIENCE 106 1 102-107 2015/01/01 
  •  PI3K INHIBITORS, PI-103, GDC-0941, AND BEZ235, OVERCOME HGFMEDIATED RESISTANCE TO EGFR-TKIS IN EGFR MUTANT LUNG CANCER Yano, Seiji;Donev, Ivan S.;Yamada, Tadaaki;Takeuchi, Shinji;Matsumoto, Kunio JOURNAL OF THORACIC ONCOLOGY 6 6 S575-S576 2011
  •  The EGFR Ligands Amphiregulin and Heparin-Binding EGF-like Growth Factor Promote Peritoneal Carcinomatosis in CXCR4-Expressing Gastric Cancer Yasumoto, Kazuo;Yamada, Tadaaki;Kawashima, Atsuhiro;Wang, Wei;Li, Qi;Donev, Ivan Shterev;Tacheuchi, Shinji;Mouri, Hisatsugu;Yamashita, Kaname;Ohtsubo, Koushiro;Yano, Seiji CLINICAL CANCER RESEARCH 17 11 3619-3630 2011
  •  Lack of association between the BIM deletion polymorphism and the risk of lung cancer with and without EGFR mutations Ebi, Hiromichi; Oze, Isao; Nakagawa, Takayuki; Ito, Hidemi; Hosono, Satoyo; Matsuda, Fumihiko; Takahashi, Meiko; Takeuchi, Shinji; Sakao, Yukinori; Hida, Toyoaki; Faber, Anthony C C; Tanaka, Hideo; Yatabe, Yasushi; Mitsudomi, Tetsuya; Yano, Seiji; Matsuo, Keitaro Journal of Thoracic Oncology 2014/11/07 
  •  Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma Li, Qi; Wang, Wei; Machino, Yusuke; Yamada, Tadaaki; Kita, Kenji; Oshima, Masanobu; Sekido, Yoshitaka; Tsuchiya, Mami; Suzuki, Yui; Nan-ya, Ken Ichiro; Iida, Shigeru; Nakamura, Kazuyasu; Iwakiri, Shotaro; Itoi, Kazumi; Yano, Seiji Cancer Science 2014/01/01 
  •  Expression of Akt Kinase-interacting protein 1, a scaffold protein of the PI3K/PDK1/Akt pathway, in pancreatic cancer Ohtsubo, Koushiro; Yamada, Tadaaki; Zhao, Lu; Jin, Tiefeng; Takeuchi, Shinji; Mouri, Hisatsugu; Yamashita, Kaname; Yasumoto, Kazuo; Fujita, Naoya; Kitagawa, Hirohisa; Ohta, Tetsuo; Ikeda, Hiroko; Yano, Seiji Pancreas 43 7 1093-1100 2014/01/01 
  •  [A case of poorly-differentiated neuroendocrine carcinoma of the ascending colon with multiple liver metastases successfully treated with cisplatin and irinotecan]. Yamashita, Kaname; Ishikawa, Daisuke; Nanjo, Shigeki; Takeuchi, Shinji; Yamada, Tadaaki; Mouri, Hisatsugu; Ohtsubo, Koushiro; Yasumoto, Kazuo; Kumagai, Masashi; Ueda, Yoshimichi; Yano, Seiji Gan to kagaku ryoho. Cancer & chemotherapy 39 9 1427-1430 2012/09/01 
  •  Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: Sensitivity and resistance Takeuchi, Shinji; Yano, Seiji Respiratory Investigation 52 6 348-356 2014/01/01 
  •  Distinct allelic expression patterns of imprinted IGF2 in adenocarcinoma and squamous cell carcinoma of the lung Ozaki, Satoru; Kawahara, Ei; Maenaka, Shiori; Hoang, Nguyenviet; Oyama, Takeru; Imai, Miwa; Oda, Makoto; Yano, Seiji Oncology Letters 8 6 2561-2564 2014/01/01 

Conference Presentations

Arts and Fieldwork

Patent

Theme to the desired joint research

○Molecular targeted therapy for pleural mesothelioma
○Reserach for investigating resistance mechanism to molecular targeted drugs in lung cancer

Grant-in-Aid for Scientific Research

○「胸膜中皮腫に著効を示すVEGF受容体阻害薬の真の標的分子同定と治療への応用」(2007-) 
○「HGFによるEGFR活性型変異養成肺癌の分子標的薬耐性を克服する個別化医療開発」(2009-) 
○「肺癌転移の臓器微小環境特性から見た分子標的治療法の開発」(2005-) 
○「3学会合同「がんゲノムネット」を用いた,国民への「がんゲノム医療」に関する教育と正しい情報伝達に関する研究」(2018-2020) 
○「分子標的薬で肺がんの根治を目指す治療の非臨床研究基盤の形成」(2019-2021) 
○「遺伝子スクリーニング基盤(LC-SCRUM-Japan)を利用した,MET遺伝子異常陽性の進行非小細胞肺癌に対する治療開発を目指した研究」(2018-2020) 
○「MAPKシグナル抑制が誘導するフィードバック機構の不均一性解明と制御に基づくKRAS/BRAF変異腫瘍に対する新規治療開発」(2016-2021) 
○「RET肺がんに対するアレクチニブの医師主導治験と耐性機構解析」(2018-2020) 
○「肺がんの髄膜がん腫症における分子標的薬耐性を克服する研究」(2016-2018) 
○「肺がんの転移と分子標的薬耐性を克服する統合的研究」(2012-2014) 
○「呼吸器悪性腫瘍の微小環境の特性を標的とした新規制御法の開発」(2010-2011) 
○「HGFによるEGFR活性型変異陽性肺癌の分子標的薬耐性を克服する個別化医療開発」(2009-2011) 

Classes (Bachelors)

Classes (Graduate Schools)

○Seminar on Clinical Oncology(2017)
○Seminar of Cancer Pharmacology(2017)
○Itemized Lectures on Cancer Pharmacology(2017)
○Itemized Lectures on Cancer Pharmacology(2017)
○Introduction to Medicine(2017)
○Molecular Oncology(2017)
○Seminar on Clinical Oncology(2017)
○Seminar on Clinical Oncology(2017)
○Itemized Lectures on Cancer Pharmacology(2017)
○Seminar of Cancer Pharmacology(2017)
○Seminar of Cancer Pharmacology(2017)
○Itemized Lectures on Cancer Pharmacology(2016)
○Seminar on Clinical Oncology(2016)
○Seminar of Cancer Pharmacology(2016)
○Seminar of Cancer Pharmacology(2016)
○Itemized Lectures on Cancer Pharmacology(2016)
○Seminar on Clinical Oncology(2016)
○Seminar of Cancer Pharmacology(2016)
○Seminar on Clinical Oncology(2016)
○Itemized Lectures on Cancer Pharmacology(2016)
○Molecular Oncology(2016)
○Introduction to Medicine(2016)

International Project

International Students

Lecture themes

Others (Social Activities)

To Page Top